|
Volumn 88, Issue 1, 2002, Pages 6-9
|
Blood transfusion in critical illness
|
Author keywords
[No Author keywords available]
|
Indexed keywords
2,3 DIPHOSPHOGLYCERIC ACID;
HEMOGLOBIN;
OXYGEN;
ANEMIA;
ANIMAL CELL;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
BLOOD GROUP ABO INCOMPATIBILITY;
BLOOD TRANSFUSION;
BLOOD VOLUME;
CELLULAR IMMUNITY;
CLINICAL PRACTICE;
COMORBIDITY;
CONTROLLED STUDY;
COST EFFECTIVENESS ANALYSIS;
CRITICAL ILLNESS;
DISEASE ASSOCIATION;
DISEASE SEVERITY;
EDITORIAL;
ERYTHROCYTE SHAPE;
HEALTH CARE COST;
HEPATITIS VIRUS;
HOSPITAL ADMISSION;
HUMAN;
HUMAN CELL;
HUMAN IMMUNODEFICIENCY VIRUS;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
IMMUNE DEFICIENCY;
INFECTIOUS HEPATITIS;
INTENSIVE CARE UNIT;
LEUKOCYTOSIS;
MEDICAL DECISION MAKING;
MORTALITY;
NONHUMAN;
OXYGEN TRANSPORT;
PREOPERATIVE EVALUATION;
PRIORITY JOURNAL;
RAT;
RISK ASSESSMENT;
RISK BENEFIT ANALYSIS;
SAFETY;
SYMPTOM;
TREATMENT INDICATION;
|
EID: 0036139844
PISSN: 00070912
EISSN: None
Source Type: Journal
DOI: 10.1093/bja/88.1.6 Document Type: Editorial |
Times cited : (19)
|
References (30)
|